Tofacitinib and Pulmonary embolism - a phase IV clinical study of FDA data

Summary:

Pulmonary embolism is reported as a side effect among people who take Tofacitinib (tofacitinib), especially for people who are male, 60+ old, have been taking the drug for 6 - 12 months also take Humira, and have Enterocolitis.

The phase IV clinical study analyzes which people have Pulmonary embolism when taking Tofacitinib. It is created by eHealthMe based on reports of 5,544 people who have side effects when taking Tofacitinib from the FDA, and is updated regularly.

What is Tofacitinib?

Tofacitinib has active ingredients of tofacitinib. eHealthMe is studying from 5,554 Tofacitinib users. Check the latest studies of Tofacitinib.

What is Pulmonary embolism?

Pulmonary embolism (blockage of the main artery of the lung) is found to be associated with 2,333 drugs and 2,956 conditions by eHealthMe. Check the latest studies of Pulmonary embolism.

On Jul, 14, 2026

5,544 people reported to have side effects when taking Tofacitinib.
Among them, 61 people (1.1%) have Pulmonary embolism.

Could Tofacitinib cause Pulmonary embolism?

Among these 61 people:

How long have people been on Tofacitinib when they have Pulmonary embolism? *

What is the gender of people who have Pulmonary embolism when taking Tofacitinib? *

female: 36.11 %
male: 63.89 %

What is the age of people who have Pulmonary embolism when taking Tofacitinib? *

What are other drugs people take besides Tofacitinib? *

What are other side effects people have besides Pulmonary embolism? *

Drug Ineffective: 35 people, 57.38%
Diarrhea: 34 people, 55.74%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 24 people, 39.34%
Sepsis (a severe blood infection that can lead to organ failure and death): 19 people, 31.15%
Rashes (redness): 19 people, 31.15%
Hypotension (abnormally low blood pressure): 18 people, 29.51%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 18 people, 29.51%
Pneumonia: 18 people, 29.51%
Fever: 18 people, 29.51%
Neoplasm Progression (growth of tumour): 17 people, 27.87%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 12 people, 19.67%
Enterocolitis (inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon): 12 people, 19.67%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 5 people, 8.20%
Malignant Melanoma (skin cancer rises from melancytes): 5 people, 8.20%
Colitis (inflammation of colon): 3 people, 4.92%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 2 people, 3.28%
Urinary Tract Infection: 1 person, 1.64%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 1.64%
Pain: 1 person, 1.64%
Ill-Defined Disorder: 1 person, 1.64%

* Approximation only. Some reports may have incomplete information.

Do you take Tofacitinib and have Pulmonary embolism?

- Check whether Pulmonary embolism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tofacitinib:

Tofacitinib (5,554 reports)

Browse all side effects of Tofacitinib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary embolism:

Pulmonary embolism (2,333 drugs)

Browse all the conditions that are associated with Pulmonary embolism:

Pulmonary embolism (2,956 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tofacitinib (the active ingredients of Tofacitinib) and Tofacitinib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.